Skip to main content
. Author manuscript; available in PMC: 2021 Feb 14.
Published in final edited form as: Neuropharmacology. 2019 Oct 22;162:107827. doi: 10.1016/j.neuropharm.2019.107827

Figure 3.

Figure 3.

AQmabAM protection against complement-dependent cytotoxicity produced by rAb-53 and human complement. A. (Left) CHO-AQP4 cells were pre-incubated with AQmabAM for 1 h, followed by addition of rAb-53 and human complement for 1 h. Cytotoxicity was assayed using Alamar blue. (Right) Percentage cytotoxicity as a function of AQmabAM concentration for measurements done at different rAb-53 concentrations (mean ± S.E.M., n=3). B. Comparison of cytotoxicity with AQmabAM added 1 h before, together with, or 1 h after rAb-53, followed by 2% human complement for an additional hour. Percentage cytotoxicity as a function of AQmabAM concentration (mean ± S.E.M., n=3). C. Percentage cytotoxicity as in A, comparing protection by the original rAb-53-based aquaporumab (AQmab) and AQmabAM.